C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins. Its lead product candidate is Cemsidomide, an orally bioavailable monodac targeting IKZF1 and IKZF3, or IKZF1/3 to address a need across multiple lines of therapy in multiple myeloma, which has competed its phase 1. The company is also developing oncology product candidate, CFT8919, an orally bioavailable, allosteric, mutant-selective bidac degrader of epidermal growth factor receptor, with an L858R mutation in non-small cell lung cancer; and new degraders focused on inflammation, neuroinflammation, and neurodegeneration. It has strategic collaborations F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc., Betta Pharmaceuticals Co. Ltd., and Merck KGAA. Additionally, it has a collaboration agreement with Roche Holding AG for the development of Degrader-Antibody Conjugates for cancer treatment. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts. Show more

490 Arsenal Way, Watertown, MA, 02472, United States

Biotechnology

Healthcare

Market Cap

281M

52 Wk Range

$1.21 - $3.82

Previous Close

$2.97

Open

$2.96

Volume

2,142,821

Day Range

$2.77 - $3.01

Enterprise Value

92.47M

Cash

248.5M

Avg Qtr Burn

-22.15M

Insider Ownership

8.65%

Institutional Own.

77.65%

Qtr Updated

12/31/25

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Cemsidomide (CFT7455) +/- dexamethasone Details Hematologic malignancies, Blood disorder, Non-Hodgkin lymphoma, Blood cancer, Multiple myeloma	Phase 1b Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
CFT1946 (mono) +/- cetuximab Details Cancer, V600 Mutant Cancers, Solid tumor/s, Colorectal cancer, Melanoma	Phase 1 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
CFT8919 (EGFR) Details Solid tumor/s, Non-small cell lung carcinoma, Cancer	Phase 1 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
CFT8634 (BiDAC) Details Rare diseases, Cancer	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.